Paclitaxel
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Paclitaxel: From Established Chemotherapy Use to Predicted Female Breast Carcinoma
One-Sentence Summary
Paclitaxel is a taxane-class microtubule-stabilizing cytotoxic agent used broadly in oncology. The TxGNN model’s top prediction for this drug is Female Breast Carcinoma, supported by 62 clinical trials, but breast cancer is already a well-established, globally approved indication for paclitaxel — meaning this “prediction” largely reconfirms known clinical practice rather than identifying a genuinely novel repurposing opportunity. A more clinically distinct signal appears at rank 5 (hormone-resistant breast carcinoma), where a Phase 3 RCT directly supports sequencing paclitaxel after endocrine-therapy failure.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the source dataset (0 Taiwan/US regulatory licenses on file — see Data Gap DG001/DG002). Paclitaxel is a globally established taxane chemotherapy already indicated for ovarian, breast, and non-small cell lung cancer, and Kaposi sarcoma. |
| Predicted New Indication | Female Breast Carcinoma (⚠ already a standard approved use — see caveat below) |
| TxGNN Prediction Score | 99.99% (rank 250 of all candidates) |
| Evidence Level | L1 |
| US Market Status | Not Marketed (per dataset; 0 licenses on file) |
| Number of NDAs | 0 |
| Recommended Decision | Hold — Not a Novel Repurposing Candidate (see rationale below) |
⚠ Key Caveat: The evidence pack’s own mechanistic annotation for this candidate states explicitly: “This is not a novel repurposing candidate but an existing standard-of-care use; the KG prediction merely reproduces a known fact.” This is reflected in the recommendation above, which diverges from the raw scoring-engine output (“Proceed with Guardrails”) because that score reflects treatment efficacy evidence, not repurposing novelty.
Why is This Prediction Reasonable?
Detailed, structured mechanism-of-action data (DrugBank MOA field) was not available in this evidence pack (Data Gap DG002, High severity). Based on the pharmacological literature and the model’s own annotations, paclitaxel is a taxane that binds and stabilizes microtubules, preventing spindle depolymerization and thereby blocking mitosis in rapidly proliferating cells — a classic broad-spectrum cytotoxic mechanism.
Breast cancer is one of the core, long-established indications for paclitaxel worldwide (used across neoadjuvant, adjuvant, and metastatic settings, often combined with anthracyclines, platinum agents, or HER2-targeted therapy). Because of this, the mechanistic link between paclitaxel and breast carcinoma is not merely “plausible” — it is already clinically validated and guideline-endorsed. The high TxGNN score for this pairing most likely reflects the density of existing drug–disease co-occurrence in the knowledge graph rather than a novel biological hypothesis.
The more informative signal in this evidence pack is the breast cancer subtype/context stratification the model surfaces — particularly rank 5, “hormone-resistant breast carcinoma.” Here paclitaxel’s non-hormone-dependent, direct cytotoxic mechanism offers a genuine rationale for treatment-sequencing after endocrine-therapy failure, which is a more clinically actionable framing than the generic “breast carcinoma” prediction.
Clinical Trial Evidence
(Evidence for the top-ranked prediction: Female Breast Carcinoma)
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00016406 | Phase 3 | Completed | 399 | AC → weekly paclitaxel ± filgrastim in inflammatory/locally advanced breast cancer; direct comparator RCT (Grade A) |
| NCT00014222 | Phase 3 | Completed | 2,104 | Large adjuvant trial comparing EC+filgrastim+epoetin→paclitaxel vs. AC→paclitaxel vs. CEF in node-positive/high-risk breast cancer |
| NCT00003612 | Phase 2 | Completed | 92 | Paclitaxel + carboplatin + trastuzumab in HER2-overexpressing metastatic breast cancer (Grade B) |
| NCT04159142 | Phase 2 | Recruiting | 414 | Nab-paclitaxel + carboplatin vs. nab-paclitaxel + capecitabine in advanced triple-negative breast cancer |
| NCT00003992 | Phase 2 | Completed | 200 | Paclitaxel-trastuzumab adjuvant therapy for stage II/IIIA HER2-overexpressing breast cancer |
| NCT01705691 | Phase 2 | Completed | 50 | Weekly paclitaxel vs. eribulin → AC as neoadjuvant therapy, HER2-negative breast cancer (NSABP FB-9) |
| NCT00003539 | Phase 2 | Completed | 50 | Weekly paclitaxel + trastuzumab in metastatic breast cancer |
| NCT02413320 | Phase 2 | Completed | 101 | Carboplatin+docetaxel or carboplatin+paclitaxel → AC in stage I-III triple-negative breast cancer |
| NCT04440930 | NA | Completed | 88 | White tea mouthwash for prevention of paclitaxel-induced oral mucositis (supportive care, not efficacy; Grade C) |
| NCT00589238 | Phase 2 | Terminated | 16 | Neoadjuvant weekly paclitaxel+carboplatin vs. paclitaxel alone → AC in basal-like breast cancer |
Literature Evidence
Currently no related literature available for this specific candidate (female breast carcinoma) in the evidence pack — all citation evidence for this prediction was clinical-trial based.
(Note: a Tier-1 RCT does exist for the related, more clinically distinct candidate “hormone-resistant breast carcinoma” — PMID 20462978, SELECT BC trial, taxane vs. TS-1 in metastatic/recurrent hormone-resistant breast cancer — see Conclusion for follow-up recommendation.)
Cytotoxicity
Paclitaxel is a conventional cytotoxic chemotherapy agent (taxane class); this section is included per antineoplastic-drug criteria.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (Taxane — microtubule-stabilizing agent) |
| Myelosuppression Risk | High — neutropenia is a well-recognized dose-limiting toxicity; several trials in this dataset paired paclitaxel with growth-factor support (e.g., filgrastim in NCT00016406, NCT00014222) |
| Emetogenicity Classification | Low to Moderate (standard oncology classification for IV paclitaxel) |
| Monitoring Items | CBC with differential, liver and renal function, infusion-related hypersensitivity reactions, peripheral neuropathy assessment |
| Handling Protection | Requires standard hazardous/cytotoxic drug handling precautions (closed-system transfer devices, PPE per institutional cytotoxic handling policy) |
Please refer to the package insert warnings and precautions for the definitive, product-specific toxicity profile — formal TFDA label data was not available in this dataset (Data Gap DG001, Blocking severity).
Safety Considerations
Please refer to the package insert for safety information. No structured key warnings, contraindications, or drug-drug interaction data were available in this evidence pack (DG001: TFDA warnings/contraindications — Blocking; DDI query returned no results).
Conclusion and Next Steps
Decision: Hold — Not a Novel Repurposing Candidate
Rationale:
- The top TxGNN prediction (female breast carcinoma) is already a long-established, globally approved indication for paclitaxel; the evidence pack’s own mechanistic annotation confirms this is a reproduction of known clinical fact rather than a new therapeutic hypothesis. Advancing this as a “repurposing candidate” would be evaluatively misleading despite the strong (L1) trial evidence base.
- A more genuinely distinct and clinically actionable signal exists at rank 5, “hormone-resistant breast carcinoma” (L2 evidence, including a Tier-1 RCT, PMID 20462978), which reflects a specific treatment-sequencing rationale (chemotherapy after endocrine-therapy failure) rather than a duplicate of the base indication.
- Two other predictions (Ehrlich tumor, rank 3; nipple carcinoma, rank 8) are supported only by animal-model or case-report-level evidence, and two (parameningeal/vaginal embryonal rhabdomyosarcoma, ranks 9–10) have zero clinical trial or literature support — none of these should proceed without substantial additional evidence.
To proceed, the following is needed:
- Confirm paclitaxel’s actual approved indications (TFDA/FDA label) to properly benchmark novelty of any candidate against current standard of care
- Obtain formal DrugBank/regulatory MOA documentation (Data Gap DG002)
- Obtain TFDA package insert warnings, contraindications, and DDI data (Data Gap DG001, Blocking — required before any S1 safety review)
- If pursuing a genuinely differentiated research question, reframe evaluation around the “hormone-resistant breast carcinoma” subgroup (rank 5) rather than generic “breast carcinoma”
- Disregard the parameningeal/vaginal rhabdomyosarcoma and Ehrlich tumor candidates pending any real-world clinical or preclinical corroboration beyond the KG similarity score
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.